Aortic Valve Prosthesis

The sole aortic mechanical valve that has been approved by the FDA, Health Canada, and CE Mark for low INRs of 1.5–2.0.1*

Clinically demonstrated to be safer with reduced anticoagulation, resulting in an 87% reduction in bleeding, with no increase in thromboembolism and no valve thrombosis.Two*

In comparison to other mechanical and bioprosthetic aortic valves, the optimal hemodynamics are achieved at a minimum of one year due to the unique material and design.1, 3, and 7input:
output:*Decrease the INR after three months of standard therapy.1input:
output:Clinical Evidence

With a 50% reduction in INR1, the risk of bleeding is reduced by 87%.

The 5-year interim data of the On-X Aortic Heart Valve Post Approval Study (PAS) revealed that the On-X Aortic Valve reduces major bleeding (MB) by 87% in a real-world setting, while there is no increase in thromboembolism (TE) or valve thrombosis (VT) when managed at a low INR of 1.5-2.0, in comparison to the standard INR of 2.0-3.0.*1. The INR for all other mechanical aortic valve anticoagulation should be maintained at 2.0-3.0.2.input:
output:*Decrease the INR after three months of standard therapy following the operation.OPTIMAL HEMODYNAMICS

In comparison to other bioprosthetic and bileaflet aortic valves, the On-X Aortic Valve provides optimal mean gradients at a minimum of one year.Four to nine